Similar articles

• Immunoreactive insulin, glucose tolerance, and carbohydrate inducibility in types II, 3, IV, and V hyperlipoproteinemia.

  Glueck CJ, Levy RI, Fredrickson DS. Glueck CJ, et al. Diabetes. 1969 Nov;18(11):739-47. doi: 10.2337/diab.18.11.739. Diabetes. 1969. PMID: 5348517 No abstract available.
• [Thyroid gland dysfunction and metabolic abnormalities, with special reference to abnormal lipid and glucose metabolism].

  Mashita K, Tarui S. Mashita K, et al. Nihon Rinsho. 1980;38(3):1656-65. Nihon Rinsho. 1980. PMID: 6993732 Review. Japanese. No abstract available.
• Plasma triglycerides in human diabetes.

  Nikkilä EA. Nikkilä EA. Proc R Soc Med. 1974 Jun;67(7):662-5. doi: 10.1177/003591577406700737. Proc R Soc Med. 1974. PMID: 4212245 Free PMC article. No abstract available.
• Effect of clofibrate on plasma glucose and serum immunoreactive insulin in patients with hyperlipoproteinemia.

  Fenderson RW Jr, Sekowski I, Mohan C, Deutsch S, Benjamin F, Samuel P. Fenderson RW Jr, et al. Am J Clin Nutr. 1974 Jan;27(1):22-8. doi: 10.1093/ajcn/27.1.22. Am J Clin Nutr. 1974. PMID: 4809201 No abstract available.
• Hypertriglyceridemia, diabetes mellitus, and coronary vessel disease.

  Levy RI, Glueck CJ. Levy RI, et al. Arch Intern Med. 1969 Mar;123(3):220-8. Arch Intern Med. 1969. PMID: 4886256 Review. No abstract available.